Journal of Blood Disorders & Transfusion

Association of xenobiotic metabolizing enzymes gene polymorphism with hepatocellular carcinoma in Egyptian patients

7^th World Hematologists Congress

May 08-09, 2017 Barcelona, Spain

Manar Obada, Ashraf El-Fert, Asmaa Gomaa, Mohamed Hashim, Mohamed Kohla, Wael Abdelrazek, Om kolsoum Elhadad and Hala El-Said

National Liver Institute- Menoufia University, Egypt

Posters & Accepted Abstracts: J Blood Disord Transfus

Abstract:

Background & Aim: Xenobiotics are metabolized by a large number of metabolizing enzymes, genetic polymorphism of their genes are suggested as modifiers of cancer risk. The present study aimed to investigate the association between xenobiotic metabolizing enzymes [cytochrome P450 (CYP), N-acetyl transferase 2 (NAT2) and UDP-glucuronosyltransferase (UGT)] gene polymorphism with the risk of HCC in patients with chronic HCV-induced cirrhosis. Methods: This study was performed on 354 subjects, divided into three groups, (group I: 150 hepatocellular carcinoma (HCC) patients, group II: 104 patients with HCV-related chronic liver disease (CLD) and group III: 100 apparently healthy control). The studied genes were genotyped using polymerase chain reaction-restriction fragment length polymorphism and allelic discrimination assays. Results: Genetic polymorphic patterns of NAT2 (M1 and M3), CYP2D 6*6, CYP2D 6*4 and CYP2D 6*3 showed a significant difference in HCC group compared to other groups. NAT2 M2 slow acetylator, CYP2D6*6 and CYP2D6*3 poor metabolizers and CYP2D 6*4 rapid metabolizer were associated with increased HCC risk (OR: 1.23, 4.0, 3.32 and 2.3 respectively). Conclusion: Increased risk for hepatocellular carcinoma in Egyptian patients infected with HCV may be associated with the genotypes: NAT2 (M2), CYP2D 6*6, CYP2D 6*4 and CYP2D6*3 and thus could help in tailoring individualized therapy and serve as potential target sites for chemotherapy.

Biography :

Email: manarobada@yahoo.com